TRAIL expression by activated human CD4(+)V alpha 24NKT cells induces in vitro and in vivo apoptosis of human acute myeloid leukemia cells.
Human Valpha24NKT cells are activated by alpha-galactosylceramide (alpha-GalCer)-pulsed dendritic cells in a CD1d-dependent and a T-cell receptor-mediated manner. Here, we demonstrate that CD4(+)V alpha 24NKT cells derived from a patient with acute myeloid leukemia (AML) M4 are phenotypically similar to those of healthy donors and, in common with those derived from healthy donors, express tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) when the cells are activated by alpha-GalCer-pulsed dendritic cells but not prior to activation. We also show that myeloid leukemia cells from patients with AML M4, but not from patients with AML M0 or M1, undergo apoptosis following culture with TRAIL-expressing autologous or allogeneic healthy donor V alpha 24NKT cells. Apoptosis of AML M4 leukemia cells from patient peripheral blood was almost completely blocked by a neutralizing monoclonal antibody against TRAIL, indicating that TRAIL on V alpha 24NKT cells is essential for the induction of apoptosis in AML M4 leukemia cells. A nonobese diabetic-severe combined immunodeficient human leukemia (AML M4) model showed that human activated CD4(+)V alpha 24NKT cells induced apoptosis of human leukemia cells in vivo. This is the first evidence that activated V alpha 24NKT cells express TRAIL and that TRAIL causes apoptosis of monocytic leukemia cells from patients with AML M4 in vitro and in vivo. Adoptive immune therapy with activated V alpha 24NKT cells, or other strategies to increase activated V alpha 24NKT cells in vivo, may be of benefit to patients with AML M4. (Blood. 2001;97:2067-2074)
Nieda
M
M
Department of Research of the Japanese Red Cross Central Blood Center; Japanase Red Cross Hospital, Tokyo, Japan. nieda@cbc.jrc.or.jp
Nicol
A
A
Koezuka
Y
Y
Kikuchi
A
A
Lapteva
N
N
Tanaka
Y
Y
Tokunaga
K
K
Suzuki
K
K
Kayagaki
N
N
Yagita
H
H
Hirai
H
H
Juji
T
T
D000328:Adult; D000818:Animals; D000911:Antibodies, Monoclonal / Q000276:immunology; D018949:Antigens, CD1 / Q000502:physiology; D055610:Antigens, CD1d; D017209:Apoptosis / Q000502:physiology*; D051017:Apoptosis Regulatory Proteins; D015496:CD4-Positive T-Lymphocytes / Q000145:classification / Q000276:immunology / Q000378:metabolism* / Q000637:transplantation; D002478:Cells, Cultured; D018920:Coculture Techniques; D003713:Dendritic Cells / Q000276:immunology*; D005260:Female; D005312:Fetal Blood / Q000166:cytology; D005699:Galactosylceramides / Q000494:pharmacology*; D006412:Hematopoietic Stem Cells / Q000378:metabolism; D006801:Humans; D016219:Immunotherapy, Adoptive; D007951:Leukemia, Myeloid / Q000473:pathology; D015470:Leukemia, Myeloid, Acute / Q000473:pathology; D015479:Leukemia, Myelomonocytic, Acute / Q000276:immunology / Q000473:pathology* / Q000628:therapy; D008213:Lymphocyte Activation; D008297:Male; D008562:Membrane Glycoproteins / Q000037:antagonists & inhibitors / Q000096:biosynthesis / Q000276:immunology / Q000502:physiology*; D051379:Mice; D016688:Mice, Inbred NOD; D016513:Mice, SCID; D008875:Middle Aged; D009368:Neoplasm Transplantation; D014411:Neoplastic Stem Cells / Q000378:metabolism; D011948:Receptors, Antigen, T-Cell / Q000276:immunology; D016176:T-Lymphocyte Subsets / Q000276:immunology / Q000378:metabolism* / Q000637:transplantation; D053221:TNF-Related Apoptosis-Inducing Ligand; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors / Q000096:biosynthesis / Q000276:immunology / Q000502:physiology*; D023041:Xenograft Model Antitumor Assays
D000911:Antibodies, Monoclonal; D018949:Antigens, CD1; D055610:Antigens, CD1d; D051017:Apoptosis Regulatory Proteins; C526877:CD1D protein, human; D005699:Galactosylceramides; D008562:Membrane Glycoproteins; D011948:Receptors, Antigen, T-Cell; D053221:TNF-Related Apoptosis-Inducing Ligand; C505653:TNFSF10 protein, human; C505654:Tnfsf10 protein, mouse; D014409:Tumor Necrosis Factor-alpha